Skip to Main Content

Paper Details

Evaluating the Duration of Response With Mirvetuximab Soravtansine for Treating Platinum-Resistant Ovarian Cancer.
J Clin Oncol
1
2023
Author NameAffiliation
Lu TianStanford University, Harvard T.H. Chan School of Public Health
  • 1 - 1

Datasets

Release 1.2